Scientific Program Day Two
Thursday | June 27, 2024
과학 프로그램 2 일 차
科学议程第一天
カンファレンス ２日目
7:00 am Coffee & Check-In
7:50 am Chair’s Opening Remarks
Identifying Novel Targets & Their Benefits to Diversify ADC Programs & Design a More Accurate ADC
8:00 am Unmet Needs in ADCs for Gastrointestinal Cancer: East-West Differences & Novel Target Strategies Beyond HER2 & TROP2
Synopsis
- Addressing the unmet needs of ADCs in gastrointestinal cancers
- Discussing the regional differences in the need for an ADC for gastrointestinal cancers
- Going beyond HER2 and TROP2: Novel targets for ADCs in gastrointestinal cancers
8:30 am Developing a Precise ADC for Novel Targets to Take Your ADC From Bench to Bedside
Synopsis
- Exploring target discovery for ADCs
- Understanding pre-clinical and clinical translation
- Developing the best-in-class ADC for precision oncology
9:00 am SGN-B6A: A Vedotin Antibody-Drug Conjugate that Targets Integrin Beta-6 & Shows Clinical Efficacy in Multiple Solid Tumor Indications
Synopsis
- Explore how SGN-B6A is an investigational, first-in-class ADC, which shows high specificity towards integrin beta-6
- Overview of SGN-B6A preclinical and clinical safety and efficacy data
- Discuss the rationale for clinical combination between SGN-B6A and CPIs
9:30 am Versatile & Robust Chemical Site-Specific Conjugation Platform: AJICAP® Technology
Synopsis
- AJICAP®️ Conjugation: Examining how site-specific technologies are being employed in many of the next-generation ADCs due to the enhancement of clinically relevant biological properties observed in various preclinical studies
- AJICAP®️ Linker: Demonstrating a novel hydrophilic linker technology that enables the versatile synthesis of homogenous DAR = 1, 2, 4, 8, and higher
- Showcasing Bispecific and Trispecific antibodies produced by fully-chemical conjugation technology
10:00 am Morning Networking Break
11:00 am NN3201, a Novel C-Kit Targeting ADC, Exhibits Robust Preclinical AntiTumor Efficacy in SCLC & GIST Models
Synopsis
- Navigating the effects of NN3201 in small cell lung cancer
- Exploring a novel C-Kit targeting ADC
- Showing anti-tumor efficacy in SCLC and GIST models
Innovating Novel Linker & Payload Technologies to Increase Stability, Efficiency & Patient Treatability
11:30 am Delivery of BET Protein Degrader to Pancreatic Cancer & Their Microenvironment Via CEACAM6-Targeted Antibody–Drug Conjugate
Synopsis
- Analyzing Antibody protein degrader conjugate
- Understanding pancreatic cancer and its effects
- Reviewing a novel payload, BET protein degrader
12:00 pm From Concept to Market: Accelerating ADC Development With WuXi XDC’s Fully Integrated Discovery & CMC Platforms
Synopsis
Session Hosted by: WuXi Biologics
- Showcasing the one-stop integrated discovery service platform focusing on bioconjugate lead selection that includes mAb/protein generation, payload linker synthesis, bioconjugate preparation, in vitro and in vivo characterization
- Demonstrating fully integrated ADC CMC development and manufacturing with industry leading DNA to IND timeline of 15 months; mAb/payload-linker/conjugation DS & DP all by in-house team and facilities
- Sharing vast ADC experience with 250+ discovery projects, 75+ CMC projects, 27+ INDs
12:30 pm
Networking Lunch
1:30 pm A Flourishing ADC space
Synopsis
- Review of the current ADC landscape, both clinical and preclinical
- Deep dive into the characteristics of ADCs in each stage of development
- Analyze trends on the recent flurry of ADC deals
2:00 pm Opening the Barn Door to ADC Discovery
Synopsis
- Discover how OmniAb® generates naturally-optimized, fully-human custom immune repertoires in multiple host species to fit any target product profile
- Learn how they mine their repertoires using high throughput B cell discovery workflows augmented by AI-guided selections
- Outline how OmniAb® offer a variety of antibody modalities including VH+VL, common light chain antibodies for bispecific applications, single domain (VHH) antibodies, and cow-inspired ultra-long CDR-H3 antibodies and picobodies
- Discuss how OmniAb’s suite of antibody discovery capabilities are well-suited to ADCs, where on-target specificity, high affinity, developability, and versatility to fit a plethora of molecular formats are all important criteria
2:30 pm Exploring Next-Generation ADC Development From Payload & Linker Perspective to Drive ADC Performance & Innovation
Synopsis
- Explore a new Topoisomerase 1 inhibitor
- Discuss a new linker system for ADC
- Review how it had better performance than Enhertu
3:00 pm Analyzing the Advantages of Protein Homeostasis by Dual Precision Approach
Synopsis
- Discover the development of a novel, catalytic payload class
- Explore diversity of degrader SAR while also enabling conjugation
- Improve potency and selectivity of delivery to target cells
3:30 pm Afternoon Networking Break
4:00 pm Talk Reserved for LegoChem Biosciences
Maximizing Therapeutic Window to Increase Efficacy & Reduce Off-Target Toxicity of Your ADC
4:30 pm PEG-Based Bispecific ADC: Better Tumor Penetration, Wider Therapeutic Window
Synopsis
- Assessing how it provides better tumor penetration
- Discussing how there were not any Fc related toxicities
- Exploring how it has a wider therapeutic window
5:00 pm Effective PK/PD Translational Strategies to Enable a Successful Early Clinical Development
Synopsis
- Defining the translational PK/PD considerations for ADC FIH starting dose prediction
- Integrating nonclinical knowledge through computational modeling and simulations to inform Phase I design dose escalations.
- Exploring translational PK/PD data to support model-informed clinical safety mitigation strategy, drug-drug interaction risks
5:30 pm Understanding How Therapeutic Window Differs From Patient to Patient to Incorporate Individual Therapy & Find the Maximum Tolerable Dose
Synopsis
- Navigating varying patient immune responses
- Using differing immune responses to individualize therapy
- Evaluating the benefits of individualized therapy